| abstract |
Disclosed is the use of levosimendan or (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide or any of their pharmaceutically acceptable salts in the absence of a further thrombolytic agent in the manufacture of a medicament for reducing the risk of hemorrhage or thrombotic or embolic occlusion of a blood vessel of the heart in a mammal having high risk of such hemorrhage or occlusion. (62) Divided Out of 550814 |